DIABETES MELLITUS AND CARDIOVASCULAR COMPLICATIONS: FOCUS ON HEMOSTASIS
https://doi.org/10.15829/1560-4071-2014-3-114-118
Abstract
This literature preview presents modern evidence on the mechanisms of prothrombotic status development in diabetes mellitus, taking into consideration the association between metabolic disturbances, increased functional platelet activity, and hemocoagulation.
About the Authors
G. G. Petrik
Kuban State Medical University, Krasnodar; S.V. Ochapovskyi Regional Clinical Hospital No. 1, Krasnodar Region, Russia
Russian Federation
Russian Federation
S. A. Pavlishchuk
Kuban State Medical University, Krasnodar
Russian Federation
Russian Federation
E. D. Kosmacheva
Kuban State Medical University, Krasnodar; S.V. Ochapovskyi Regional Clinical Hospital No. 1, Krasnodar Region, Russia.
Russian Federation
Russian Federation
References
1. Bloomgarden ZT. Cardiovascular Disease in Diabetes. Diabetes Care 2010; 33: 49-54.
2. Grant PG. Diabetes mellitus as a prothrombotic condition. J Intern Med 2007; 262: 157-72.
3. Michelson A. Platelets. Second EditionAmsterdam, Boston, Heidelberg et al.: Academic Press. Elserver Inc., 2007. p.697-711.
4. Ferreiro JL, Gomez-Hospital JA, Angiolillo DJ. Platelet abnormalities in diabetes mellitus. Diab Vasc Dis Res 2010; 7: 251-59.
5. Kim JH, Bae HY Kim SY Clinical Marker of Platelet Hyperreactivity in Diabetes Mellitus. Diabetes Metab J 2013; 37 (6): 423-28.
6. Petrik GG, Pavlishchuk SA. Metabolic parameters and hemostasis in patients with type 2 diabetes, depending on the severity of angiopathy. Problems of Endocrinology 2010; 2: 15-9. Russia. (Петрик Г. Г., Павлищук С. А. Показатели метаболизма и гемостаза у больных сахарным диабетом 2 типа в зависимости от выраженности ангиопатий. Проблемы эндокринологии 2010; 2: 15-9).
7. Schneider DJ. Factors Contributing to Increased Platelet Reactivity in People With Diabetes. Diabetes Care 2009; 32: 525-27.
8. Pavlishchuk CA, Petrik GG, Nicolskaya LF. Platelet-cell relationships with postprandial glycemia in healthy humans. Human Physiology 2004; 3: 124-27. Russia. (Павлищук СА, Петрик Г.Г., Никольская ЛФ. Тромбоцитарно-клеточные взаимоотношения при постпрандиальной гликемии у здоровых людей. Физиология человека 2004; 3: 124-27.)
9. Michno A, Bielarezyk H, Pawetczyk T, et al. Alterations of adenine nuckleotide metabolism and function of blood platelets in patients with diabetes. Diabetes 2007; 56: 462-67.
10. Sudic D, Razmara M, Forslund M. et al. High glucose levels enhance platelet activation: involvement of multiple mechanisms. Br J Haematol 2006; 133 (3): 315-22.
11. Tannock LR, King VL. Proteoglycan mediated lipoprotein retention: a mechanism of diabetic atherosclerosis. Rev Endocr Metab Disord 2008; 9: 289-30.
12. Wu G, Meininger CJ. Nitric oxide and vascular insulin resistance. Biofactors 2009; 35: 21-7.
13. Randriamboavonjy V, Fleming I. Insulin, insulin resistance, and platelet signaling in Diabetes. Diabetes Care 2009; 32: 528-30.
14. Hers I. Insulin-like growth factor-1 potentiates platelet activation via the IRS/PI3Kalpha pathway. Blood 2007; 110: 4243-52.
15. Kronenberg HM, Melmed S, Polonsky KS, et al. Texbook of Endocrinology, 11th edition. Elsevier Ltd. 2008. p.1589-631.
16. Calzada С, Coulon L, Halimi L et al. In Vitro Glycoxidized Low-Density Lipoproteins and Low-Density Lipoproteins Isolated from Type 2 Diabetic Patients Activate Platelets via p38 Mitogen-Activated Protein Kinase. The Journal of Clinical Endocrinology & Metabolism. 2007;92: 1961-64.
17. De Mattia G, Bravi MC, Laurenti O. et al. Endothelial dysfunction and oxidative stress in type 1 and type 2 diabetic patients without clinical macrovascular complications. Diabetes Res Clin Pract. 2008; 79: 337-42.
18. Nieuwdorp M, van Haeften TW, Gouverneur MC et al. Loss of endothelial glycocalyx during acute hyperglycemia coincides with endothelial dysfunction and coagulation activation in vivo. Diabetes. 2006; 55: 480-86.
19. Barillari G, Fabbro E, Pasca S, et al. Coagulation and oxidative stress plasmatic levels in a type 2 diabetes population. Blood Coagul Fibrinolysis 2009; 20: 290-96.
20. Ametov AS. Type 2 diabetes mellitus. GEOTAR-Media 2012. p492-3.
21. Pacher P, Szab C. Role of poly (ADP-ribose) polymerase-1 activation in the pathogenesis of diabetic complications: endothelial dysfunction, as a common underlying theme. Antioxid Redox Signal. 2005; 7 (11-12): 1568-80.
22. Tabit CE, Chung WB, Hamburg NM, et al. Endothelial dysfunction in diabetes mellitus: molecular mechanisms and clinical implications. Reviews in Endocrine and Metabolic Disorders 2010; 11: 61-74.
23. Lowell BB, Shulman GI. Mitochondrial dysfunction and type 2 diabetes. Science 2005; 307 (5708): 384-7.
24. Dunn EJ, Grant PJ. Type 2 diabetes: an atherothrombotic syndrome. Curr Mol Med 2005; 5:323-32.
25. Erem C, Hacihasano lu A, Celik S et al. Coagulation and fibrinolysis parameters in type 2 diabetic patients with and without diabetic vascular complications. Med Princ Pract 2005; 14: 22-30.
26. Targher G, Bertolini L, Zoppini G et al. Increased plasma markers of inflammation and endothelial dysfunction and their association with microvascular complications in Type 1 diabetic patients without clinically manifest macroangiopathy. Diabet Med 2005; 22: 999-1004.
27. Frankel DS, Meigs JB, Massaro JM et al. Von Willebrand factor, type 2 diabetes mellitus, and risk of cardiovascular disease: the framingham offspring study. Circulation 2008; 118:2533-99.
28. ^rado E., Rizzo M., Muratori I. Assotiation of elevated fibrinogen and CRP levels with carotid lesions in patiets with newly diagnosed hypertensionor type 2 diabetes. Arch Med Res 2006; 37 (8): 1004-9.
29. Festa A, Williams K, Tracy RP et al. Progression of plasminogen activator inhibitor-1 and fibrinogen levels in relation to incident type 2 diabetes. Circulation 2006; 113: 1753-59.
30. Selvin E, Marinopoulos S, Berkenblit G et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 2004; 141: 421-31.
31. Gerstein HC, Miller ME, Byington RP et al. Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-59.
32. ACCORD Study Group. Effect of Combination Lipid Therapy in Type 2 Diabetes Melitus. N Engl J Med 2010; 362: 1563-74.
33. The ADVANCE Collaborative Group. Action in Diabetes and Vascular disease: Preterax and Diamicron MR Controlled Evaluation. N Engl J Med 2008; 358: 2560-72.
34. William D, Abraira C, Moritz T, et al. Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes. N Engl J Med 2009; 360: 129-39.
Review
For citations:
Petrik G.G., Pavlishchuk S.A., Kosmacheva E.D. DIABETES MELLITUS AND CARDIOVASCULAR COMPLICATIONS: FOCUS ON HEMOSTASIS. Russian Journal of Cardiology. 2014;(3):114-118. (In Russ.) https://doi.org/10.15829/1560-4071-2014-3-114-118
Views:
733
Email this article 